Reduced adenosine deaminase activity in the CNS of spontaneously-hypertensive rats

L P Davies1, J W Hambley, G A Johnston

  • 1Department of Pharmacology, University of Sydney, NSW 2006, Australia.

Insights

Adenosine deaminase (ADA) activity is reduced in the brains of spontaneously hypertensive rats (SHR), particularly in the hypothalamus, even before significant hypertension develops. This brain-specific reduction suggests a potential role for ADA in hypertension development.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Cardiovascular Science

Background:

  • Spontaneously hypertensive rats (SHR) are a widely used animal model for studying human hypertension.
  • Adenosine deaminase (ADA) is an enzyme involved in purine metabolism, with potential roles in neurological and cardiovascular functions.

Purpose of the Study:

  • To investigate the activity of adenosine deaminase (ADA) in different brain regions and peripheral organs of spontaneously hypertensive rats (SHR) compared to normotensive WKY controls.
  • To determine if changes in ADA activity precede or coincide with the development of hypertension in SHR.

Main Methods:

  • Adenosine deaminase (ADA) activity was measured in tissue extracts from the hypothalamus, pons medulla, cerebral cortex, heart, and kidney of 30-day-old and 100-day-old SHR and WKY rats.
  • Enzyme activity was quantified using spectrophotometric assays.
  • Heat inactivation experiments were performed on pons medulla extracts to confirm enzyme specificity.

Main Results:

  • A significant reduction in ADA activity was observed in the hypothalamus (18.0%), pons medulla (20.6%), and cerebral cortex (14.7%) of 100-day-old SHR compared to WKY controls.
  • In 30-day-old SHR, a small but significant reduction in hypothalamic ADA activity (9.2%) was detected, while cerebral cortex and pons medulla showed no significant changes.
  • No significant reduction in ADA activity was found in the heart or kidney of SHR at either age.

Conclusions:

  • These findings indicate a brain-specific reduction in adenosine deaminase (ADA) activity in spontaneously hypertensive rats (SHR).
  • The observed decrease in hypothalamic ADA activity in pre-hypertensive SHR suggests a potential role for this enzyme in the early stages of hypertension development.
  • ADA activity in peripheral organs like the heart and kidney does not appear to be significantly affected by the hypertensive state in this model.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...